呼吸器吸入器：市場洞察・競合環境・市場予測 (～2030年)

呼吸器吸入器の市場規模は、2023年の302億6,749万米ドルから、予測期間中は4.65％のCAGRで推移し、2030年には405億4,087万米ドルの規模に成長すると予測されています。

呼吸器吸入器の市場は、喘息や慢性閉塞性肺疾患 (COPD) などの呼吸器疾患の有病率の上昇、技術の進歩、スマートフォンの普及の拡大、スマートヘルスソリューションの認知度向上などにより大きな成長を遂げており、これらは2024年から2030年にかけても呼吸器吸入器の大幅な需要を促進すると予測されています。

呼吸器吸入器：市場力学

世界保健機関 (WHO) が提供したデータ (2024年) によると、2019年に喘息に罹患した人は2億6,200万人でした。また、同じソースの2023年のデータによると、3億9,200万人がCOPDに罹患しており、その4分の3が低・中所得国に住むとされています。呼吸器吸入器は、喘息やCOPDを管理する上で重要な役割を果たしています。喘息患者にとって呼吸器吸入器は、発作時の迅速な緩和と、増悪を防ぐための長期的なコントロールの維持に不可欠です。COPDでは、特に重症の患者において、息苦しさなどの症状を緩和し、肺機能全体を改善するために吸入薬が使用されています。

世界の都市化の進展は、汚染の増加や座りがちなライフスタイルの採用増加などから、呼吸器疾患の増加につながっています。2022年のWHOのデータによると、2019年には世界人口の99％が空気の質がWHOのガイドラインを満たしていない地域に居住していると述べています。呼吸器吸入器は、リアルタイムのモニタリングを可能にし、個別化されたフィードバックを提供することで、治療プロトコルの遵守を向上させ、呼吸器疾患の管理に役立っています。デジタルヘルスプラットフォームとの統合は、有害な大気質やライフスタイル要因による課題に対処し、呼吸器の健康管理を最適化します。

これらのすべての要因が予測期間中の市場を牽引すると予想されています。

当レポートでは、世界の呼吸器吸入器の市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 呼吸器吸入器市場レポート：イントロダクション

• 調査範囲
• 市場の分類
• 市場の前提

第2章 呼吸器吸入器市場：エグゼクティブサマリー

• 市場概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 呼吸器吸入器市場：主要要因分析

• 市場促進要因
  • 慢性疾患の増加
  • 世界中での製品発売の増加
  • 世界中での大気汚染レベルの上昇
  • 主要な製薬企業によるデジタル技術の導入の増加
• 市場抑制要因と課題
  • 代替療法のアベイラビリティ
  • 口腔カンジダ症および真菌感染症に関連する吸入コルチコステロイド
• 市場機会
  • センサーと接続機能を備えたスマート吸入器技術の開発
  • より個別化された治療のための投与量調節機構を備えた吸入器

第6章 呼吸器吸入器市場：ポーターのファイブフォース分析

第7章 呼吸器用吸入器：市場の評価

• 製品タイプ別
  • ドライパウダー吸入器
  • 定量吸入器
  • ソフトミスト吸入器
  • ネブライザー
• タイプ別
  • 従来型吸入器
  • スマート吸入器
• 患者タイプ別
  • 成人
  • 小児
• 適応症別
  • 喘息
  • 慢性閉塞性肺疾患 (COPD)
  • その他
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 呼吸器吸入器市場：企業・製品プロファイル

• Novartis AG
• AstraZeneca
• GSK plc.
• CHIESI Farmaceutici S.p.A.
• Lupin
• Zydus Lifesciences Limited
• Teva Pharmaceutical Industries Ltd
• OMRON Corporation
• Koninklijke Philips N.V.
• PARI GmbH
• Boehringer Ingelheim International GmbH
• Glenmark Pharmaceuticals Limited
• H&T Presspart Manufacturing Ltd
• Rossmax International Ltd
• Promed Technology Co., Limited
• HELTMAN Medikal A.S.
• Pneuma Respiratory
• Cipla Inc.
• Microlife Corporation
• HONSUN

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Respiratory Inhalers Market in Global (2021-2030)
• Table 3: Respiratory Inhalers Market in Global by Product Type (2021-2030)
• Table 4: Respiratory Inhalers Market in Global by Type (2021-2030)
• Table 5: Respiratory Inhalers Market in Global by Patient Type (2021-2030)
• Table 6: Respiratory Inhalers Market in Global by Indication (2021-2030)
• Table 7: Respiratory Inhalers Market in Global by Geography (2021-2030)
• Table 8: Respiratory Inhalers Market in North America (2021-2030)
• Table 9: Respiratory Inhalers Market in the United States (2021-2030)
• Table 10: Respiratory Inhalers Market in Canada (2021-2030)
• Table 11: Respiratory Inhalers Market in Mexico (2021-2030)
• Table 12: Respiratory Inhalers Market in Europe (2021-2030)
• Table 13: Respiratory Inhalers Market in France (2021-2030)
• Table 14: Respiratory Inhalers Market in Germany (2021-2030)
• Table 15: Respiratory Inhalers Market in United Kingdom (2021-2030)
• Table 16: Respiratory Inhalers Market in Italy (2021-2030)
• Table 17: Respiratory Inhalers Market in Spain (2021-2030)
• Table 18: Respiratory Inhalers Market in the Rest of Europe (2021-2030)
• Table 19: Respiratory Inhalers Market in Asia-Pacific (2021-2030)
• Table 20: Respiratory Inhalers Market in China (2021-2030)
• Table 21: Respiratory Inhalers Market in Japan (2021-2030)
• Table 22: Respiratory Inhalers Market in India (2021-2030)
• Table 23: Respiratory Inhalers Market in Australia (2021-2030)
• Table 24: Respiratory Inhalers Market in South Korea (2021-2030)
• Table 25: Respiratory Inhalers Market in Rest of Asia-Pacific (2021-2030)
• Table 26: Respiratory Inhalers Market in the Rest of the World (2021-2030)
• Table 27: Respiratory Inhalers Market in the Middle East (2021-2030)
• Table 28: Respiratory Inhalers Market in Africa (2021-2030)
• Table 29: Respiratory Inhalers Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Respiratory Inhalers Market in Global (2021-2030)
• Figure 3: Respiratory Inhalers Market in Global by Product Type (2021-2030)
• Figure 4: Respiratory Inhalers Market in Global by Type (2021-2030)
• Figure 5: Respiratory Inhalers Market in Global by Patient Type (2021-2030)
• Figure 6: Respiratory Inhalers Market in Global by Indication (2021-2030)
• Figure 7: Respiratory Inhalers Market in Global by Geography (2021-2030)
• Figure 8: Respiratory Inhalers Market in North America (2021-2030)
• Figure 9: Respiratory Inhalers Market in the United States (2021-2030)
• Figure 10: Respiratory Inhalers Market in Canada (2021-2030)
• Figure 11: Respiratory Inhalers Market in Mexico (2021-2030)
• Figure 12: Respiratory Inhalers Market in Europe (2021-2030)
• Figure 13: Respiratory Inhalers Market in France (2021-2030)
• Figure 14: Respiratory Inhalers Market in Germany (2021-2030)
• Figure 15: Respiratory Inhalers Market in United Kingdom (2021-2030)
• Figure 16: Respiratory Inhalers Market in Italy (2021-2030)
• Figure 17: Respiratory Inhalers Market in Spain (2021-2030)
• Figure 18: Respiratory Inhalers Market in the Rest of Europe (2021-2030)
• Figure 19: Respiratory Inhalers Market in Asia-Pacific (2021-2030)
• Figure 20: Respiratory Inhalers Market in China (2021-2030)
• Figure 21: Respiratory Inhalers Market in Japan (2021-2030)
• Figure 22: Respiratory Inhalers Market in India (2021-2030)
• Figure 23: Respiratory Inhalers Market in Australia (2021-2030)
• Figure 24: Respiratory Inhalers Market in South Korea (2021-2030)
• Figure 25: Respiratory Inhalers Market in Rest of Asia-Pacific (2021-2030)
• Figure 26: Respiratory Inhalers Market in the Rest of the World (2021-2030)
• Figure 27: Respiratory Inhalers Market in the Middle East (2021-2030)
• Figure 28: Respiratory Inhalers Market in Africa (2021-2030)
• Figure 29: Respiratory Inhalers Market in South America (2021-2030)
• Figure 30: Market Drivers
• Figure 31: Market Barriers
• Figure 32: Marker Opportunities
• Figure 33: PORTER'S Five Force Analysis

Respiratory Inhalers Market by Product Type (Dry Powder Inhaler, Metred Dose Inhaler, Soft Mist Inhaler, and Nebulizers [Ultrasonic Nebulizers, Mesh Nebulizers, and Compressor Nebulizers]), Type (Conventional Inhaler Devices and Smart Inhaler Devices), Patient Type (Adult and Paediatrics), Indication (Asthma, COPD, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of respiratory disorders and rise in pollution levels worldwide

The respiratory inhalers market was valued at USD 30,267.49 million in 2023 and is likely to register a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 40,540.87 million by 2030. The respiratory inhalers market is experiencing significant growth due to the rising prevalence of respiratory conditions such as asthma & chronic obstructive pulmonary disease (COPD), coupled with advancements in technology, growing smartphone adoption, and the increasing awareness of smart health solutions, which are acting as major factors driving the substantial demand for respiratory inhalers from 2024 to 2030.

Respiratory Inhalers Market Dynamics:

According to data provided by the World Health Organization (2024), in 2019 there were 262 million people affected by asthma. As per the same source in 2023, 392 million people were living with COPD with three-quarters of them living in low and middle-income countries. Respiratory inhalers play a crucial role in managing both asthma and COPD. For asthma patients, respiratory inhalers are essential for delivering quick relief during an attack and for maintaining long-term control to prevent exacerbations. In COPD, inhalers are used to alleviate symptoms such as breathlessness and to improve overall lung function, particularly in patients with more severe forms of the disease.

The rising global urbanization led to a steady increase in respiratory illness owing to increasing pollution, and a rise in the adoption of sedentary lifestyles such as smoking which also leads to second-hand inhalation, which may also contribute to the market growth for respiratory inhalers. The WHO in 2022 stated that in 2019, 99% of the global population resided in areas where air quality did not meet the WHO's guidelines. Respiratory inhalers are instrumental in managing respiratory conditions by enabling real-time monitoring and delivering personalized feedback, thereby improving adherence to treatment protocols. Their integration with digital health platforms addresses challenges from adverse air quality and lifestyle factors, optimizing respiratory health management.

Hence, the interplay of all the above-mentioned factors is expected to drive the respiratory inhalers market during the given forecast period from 2024 to 2030.

However, the availability of alternative therapies, inhaled corticosteroids associated with oral thrush and fungal infections, among others may restrict the market growth for the respiratory inhalers market.

Respiratory Inhalers Market Segment Analysis:

Respiratory Inhalers Market by Product Type (Dry Powder Inhaler, Metred Dose Inhaler, Soft Mist Inhaler, and Nebulizers [Ultrasonic Nebulizers, Mesh Nebulizers, and Compressor Nebulizers]), Type (Conventional Inhaler Devices and Smart Inhaler Devices), Patient Type (Adult and Paediatrics), Indication (Asthma, COPD, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the respiratory inhalers market, the metered dose inhaler (MDI) category is expected to have a significant revenue share in the year 2023. The rapid growth of this product category can be attributed to the various features and applications of the MDI category.

MDIs are equipped with integrated sensors that track medication usage and monitor inhalation techniques, ensuring accurate and consistent delivery of medication. They often include real-time feedback mechanisms that alert users if they are not using the device correctly, thereby improving adherence to prescribed treatments.

Additionally, smart MDIs connect to mobile apps or digital health platforms, providing users with detailed insights into their medication patterns, symptom progression, and environmental triggers. This data can be shared with healthcare providers to facilitate personalized treatment adjustments and better disease management. Enhanced features such as dose reminders, usage tracking, and connectivity with other health devices further support comprehensive respiratory care and contribute to improved patient outcomes.

Therefore, owing to the above-mentioned factors, the demand for the MDI category upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the respiratory inhalers market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall respiratory inhalers market:

Among all the regions, North America is estimated to hold a significant revenue share in the respiratory inhalers market. This is driven by the increasing prevalence of chronic respiratory diseases and the need for improved management tools. Advancement in respiratory inhalers technology, regulatory support, and the introduction of innovative devices by key market players are anticipated to significantly propel market growth for respiratory inhalers in North America from 2024 to 2030.

According to data from the Centers for Disease Control and Prevention (2023), in 2021, approximately 11.5% of US adults aged 18 years or older were current cigarette smokers, equating to an estimated 28.3 million individuals. As per the same source, over 16 million Americans are affected by smoking-related diseases. Smoking is a major risk factor associated with the development of COPD disorder among the population.

As per data from the American Lung Association data updated in April 2024, stated that more than 34 million people are currently living in the US with chronic lung diseases like asthma and COPD. In addition to this, the same source stated that in 2023, approximately 11.7 million people in the US were living with chronic respiratory disorders, which over time makes it harder for patients to breathe. Furthermore, as per the data provided by the CDC (2023), in 2021, around 14.2 million people in the US had COPD.

Respiratory inhalers are vital in managing chronic lung diseases like asthma and COPD by delivering medication directly to the lungs, providing quick symptom relief, and helping improve respiratory function. They are essential for both immediate treatment during flare-ups and long-term control, enhancing the quality of life for those with respiratory conditions.

Various product developmental strategies such as clearances in the region by regulatory authorities in the region play a major role in pushing forward the revenue shares of respiratory inhalers in the region. For example, in June 2023 Huma received U.S. Food and Drug Administration (FDA) Class II clearance for its disease-agnostic Software as a Medical Device (SaMD) platform. The platform's device-agnostic nature enables it to integrate with external third-party devices, such as heart rate and blood sugar monitors, as well as smart inhalers, thereby expanding its functionality and versatility.

Moreover, the constant focus of market players in targeting the region in product launches is further expected to propel the growth of the North American respiratory inhalers market. For example in June 2024, Aseptika launched PUFF Clicker3, a respiratory smart inhaler dose tracker that is compatible with pressurized metered dose inhalers (pMDI) and dry powder inhalers (DPI).

Therefore, the interplay of all the factors mentioned above would provide a conducive growth environment for the North America region in the respiratory inhalers market during the forecast period from 2024 to 2030.

Respiratory Inhalers Market key players:

Some of the key market players operating in the respiratory inhalers market include Novartis AG, AstraZeneca, GSK plc., CHIESI Farmaceutici S.p.A., Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd, Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, HONSUN, and others.

Recent Developmental Activities in the Respiratory Inhalers Market:

• In August 2022, Aptar Pharma acquired the rights for Orbital dry powder inhaler. The company had acquired the worldwide rights to clinical stage drug developer Pharmaxis Orbital Inhaler, a device that had been designed to deliver high payload dry powder to the lungs.
• In February 2022, Honeywell Teams announced about their collaboration with Astrazeneca that were involved in the development of next- generation respiratory inhalers that use the near-zero global warming potential propellant.
• In October 2021, BreatheSuite announced that it received 510(k) clearance from the FDA for its metered dose inhaler V1 device that is capable of turning the existing inhalers into smart inhalers for people suffering from asthma and COPD.

Key takeaways from the Respiratory Inhalers market report study

• Market size analysis for current respiratory inhalers market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the respiratory inhalers market
• Various opportunities available for the other competitors in the respiratory inhalers market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current respiratory inhalers market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for respiratory inhalers market growth in the coming future?

Target audience who can be benefited from this Respiratory Inhalers market report study

• Respiratory inhalers device providers
• Research organizations and consulting companies
• Respiratory inhalers related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in respiratory inhalers
• Various end-users who want to know more about the respiratory inhalers market and the latest developments in the respiratory inhalers market

Frequently Asked Questions for the Respiratory Inhalers Market:

1. What are Respiratory Inhalers?

The respiratory inhalers are portable devices used to deliver medications for chronic obstructive pulmonary disease (COPD) and asthma into the airways. They are used to prevent and treat exacerbations of these chronic conditions. They offer the advantage of avoiding the systemic effects of drugs while ensuring that drugs are delivered right where they are needed.

2. What is the market for Respiratory Inhalers?

The respiratory inhalers market was valued at USD 30,267.49 million in 2023 and is likely to register a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 40,540.87 million by 2030.

3. What are the drivers for the Respiratory Inhalers market?

The respiratory inhalers market is experiencing significant growth due to the rising prevalence of respiratory conditions such as asthma & chronic obstructive pulmonary disease (COPD), coupled with advancements in technology, growing smartphone adoption, and the increasing awareness of smart health solutions, which are acting as major factors driving the substantial demand for respiratory inhalers from 2024 to 2030.

4. Who are the key players operating in the Respiratory Inhalers market?

Some of the major market key players operating in the respiratory inhalers market include Novartis AG, AstraZeneca, GSK plc., CHIESI Farmaceutici S.p.A., Lupin, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd, Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Cipla Inc., Microlife Corporation, HONSUN, and others.

5. Which region has the highest share in the Respiratory Inhalers market?

Among all the regions, North America is estimated to hold a significant revenue share in the respiratory inhalers market. This is driven by the increasing prevalence of chronic respiratory diseases and the need for improved management tools. Advancement in respiratory inhaler technology, regulatory support, and the introduction of innovative devices by key market players are anticipated to significantly propel market growth for respiratory inhalers in North America from 2024 to 2030.

Table of Contents

1. Respiratory Inhalers Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Respiratory Inhalers Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Respiratory Inhalers Market Key Factors Analysis

• 5.1. Respiratory Inhalers Market Drivers
  • 5.1.1. Increasing instances of chronic disorders
  • 5.1.2. Increasing product launches across the globe
  • 5.1.3. Rising level of air pollution worldwide
  • 5.1.4. Growing adoption of digital technology by key pharmaceutical players
• 5.2. Respiratory Inhalers Market Restraints and Challenges
  • 5.2.1. Availability of alternative therapies
  • 5.2.2. Inhaled corticosteroids associated with oral thrush and fungal infection
• 5.3. Respiratory Inhalers Market Opportunities
  • 5.3.1. Development of smart inhalers technology equipped with sensors and connectivity features
  • 5.3.2. Inhalers with adjustable dosing mechanisms for more personalized treatment

6. Respiratory Inhalers Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Respiratory Inhalers Market Assessment

• 7.1. By Product Type
  • 7.1.1. Dry-Powder Inhalers
  • 7.1.2. Metred Dosed Inhalers
  • 7.1.3. Soft Mist Inhalers
  • 7.1.4. Nebulizers
    • 7.1.4.1. Mesh Nebulizers
    • 7.1.4.2. Compressor Nebulizers
    • 7.1.4.3. Ultrasonic Nebulizers
• 7.2. By Type
  • 7.2.1. Conventional Inhaler Devices
  • 7.2.2. Smart Inhaler Devices
• 7.3. By Patient Type
  • 7.3.1. Adult
  • 7.3.2. Pediatrics
• 7.4. By Indication
  • 7.4.1. Asthma
  • 7.4.2. COPD
  • 7.4.3. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.1.2. Canada Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.1.3. Mexico Respiratory Inhalers Market Size in USD million (2021-2030)
  • 7.5.2. Europe
    • 7.5.2.1. France Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.2.2. Germany Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.2.3. United Kingdom Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.2.4. Italy Respiratory Inhalers market size in USD million (2021-2030)
    • 7.5.2.5. Spain Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.2.6. Rest of Europe Respiratory Inhalers Market Size in USD million (2021-2030)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.3.2. Japan Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.3.3. India Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.3.4. Australia Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.3.5. South Korea Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.3.6. Rest of Asia-Pacific Respiratory Inhalers Market Size in USD million (2021-2030)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.4.2. Africa Respiratory Inhalers Market Size in USD million (2021-2030)
    • 7.5.4.3. South America Respiratory Inhalers Market Size in USD million (2021-2030)

8. Respiratory Inhalers Market Company and Product Profiles

• 8.1. Novartis AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. AstraZeneca
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. GSK plc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. CHIESI Farmaceutici S.p.A.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Lupin
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Zydus Lifesciences Limited
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Teva Pharmaceutical Industries Ltd
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. OMRON Corporation
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Koninklijke Philips N.V.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. PARI GmbH
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Boehringer Ingelheim International GmbH
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Glenmark Pharmaceuticals Limited
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. H&T Presspart Manufacturing Ltd
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Rossmax International Ltd
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Promed Technology Co., Limited
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. HELTMAN Medikal A.S.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Pneuma Respiratory
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Cipla Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Microlife Corporation
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. HONSUN
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us